ABBV · AbbVie Inc.
$256.91
-2.35 (-0.91%)
At close · Jul 27
Market Cap
$458.24B
Shares
1.77B
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$10,000,000,000
as of 2018-02-15
· not restated in filings since 2018-08-07
Remaining Authorization
$1,800,000,000
as of 2026-03-31
Program Utilization
82.0%
$8,200,000,000 used of $10,000,000,000
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-03-31 YTD | $1,489,000,000 | 10-Q, filed 2026-05-08 |
| 2025-12-31 | $980,000,000 | 10-K, filed 2026-02-20 |
| 2024-12-31 | $1,708,000,000 | 10-K, filed 2026-02-20 |
| 2023-12-31 | $1,972,000,000 | 10-K, filed 2026-02-20 |
| 2022-12-31 | $1,487,000,000 | 10-K, filed 2025-02-14 |
| 2021-12-31 | $934,000,000 | 10-K, filed 2024-02-20 |
| 2020-12-31 | $978,000,000 | 10-K, filed 2023-02-17 |
| 2019-12-31 | $629,000,000 | 10-K, filed 2022-02-18 |
| 2018-12-31 | $12,014,000,000 | 10-K, filed 2021-02-19 |
| 2017-12-31 | $1,410,000,000 | 10-K, filed 2020-02-21 |
| 2016-12-31 | $6,033,000,000 | 10-K, filed 2019-02-27 |
| 2015-12-31 | $7,586,000,000 | 10-K, filed 2018-02-16 |
| 2014-12-31 | $665,000,000 | 10-K, filed 2017-02-17 |
| 2013-12-31 | $320,000,000 | 10-K, filed 2016-02-19 |
Key facts
CIK
1551152
CUSIP
00287Y109
13F (30d)
1654 filings
1600 filers
Visit website
Investor relations